Investor's Business Daily on MSN4d
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
Shares of Evolus made a doubly bullish move Tuesday on a strong preliminary fourth-quarter report and guidance for 2025.
Millennial Skin on MSN3mon
Botox vs. Jeuveau vs. Dysport: Which Wrinkle Fighter Wins?
Jeuveau’s formulation is very similar to Botox, but it’s specifically marketed for cosmetic use, which makes it a great ...
New York Post2d
NYC skincare specialist knowingly injected clients with phony Botox from China — leading one woman to experience ‘double vision’: feds
A New York City skincare specialist was busted Wednesday for injecting clients with phony Botox from China — leading one woman to experience “double vision” and heart palpitations ...
Evolus: Still Bullish, But Business Faces Tricky Challenges In '25
Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...
Business Insider3y
Botox reduces wrinkles on the face, including forehead and crow's feet
Ohara Aivaz, MD: So, there's Botox, Dysport, Xeomin, and the newest one, Jeuveau, that are all forms of botulinum toxin. Obioha: By relaxing the muscles and injecting Botox, for example ...
Evolus annonce un chiffre d'affaires net préliminaire pour le quatrième trimestre ; les actions montent avant la cloche
-- Evolus a déclaré mardi qu'elle s'attendait à un revenu net de 79 millions de dollars au quatrième trimestre, soit une ...